Merus’ (MRUS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS) in a report published on Monday,Benzinga reports. They currently have a $85.00 price objective on the biotechnology company’s stock.

Other analysts have also issued research reports about the stock. Piper Sandler started coverage on shares of Merus in a report on Thursday, February 13th. They set an “overweight” rating and a $84.00 target price on the stock. Wells Fargo & Company started coverage on shares of Merus in a research note on Friday, February 7th. They issued an “overweight” rating and a $91.00 price target for the company. Needham & Company LLC cut their price target on shares of Merus from $85.00 to $83.00 and set a “buy” rating for the company in a research note on Friday, February 28th. The Goldman Sachs Group began coverage on shares of Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 price target for the company. Finally, Citigroup increased their target price on shares of Merus from $89.00 to $97.00 and gave the company a “buy” rating in a report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $85.77.

Merus Stock Up 3.7 %

MRUS opened at $46.29 on Monday. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of -11.72 and a beta of 1.11. Merus has a twelve month low of $37.77 and a twelve month high of $61.61. The company’s 50-day moving average price is $42.14 and its two-hundred day moving average price is $46.65.

Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.48. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The company had revenue of $9.14 million for the quarter, compared to analyst estimates of $10.57 million. As a group, sell-side analysts anticipate that Merus will post -3.85 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of MRUS. Boxer Capital Management LLC purchased a new position in Merus during the 4th quarter valued at about $79,895,000. Wellington Management Group LLP raised its holdings in Merus by 73.6% in the third quarter. Wellington Management Group LLP now owns 2,887,514 shares of the biotechnology company’s stock worth $144,260,000 after buying an additional 1,224,573 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in Merus by 56.8% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company’s stock worth $89,356,000 after buying an additional 770,000 shares during the last quarter. FMR LLC raised its holdings in Merus by 10.4% in the third quarter. FMR LLC now owns 6,873,926 shares of the biotechnology company’s stock worth $343,421,000 after buying an additional 648,994 shares during the last quarter. Finally, Westfield Capital Management Co. LP purchased a new position in Merus in the third quarter worth about $30,399,000. 96.14% of the stock is owned by hedge funds and other institutional investors.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.